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by G-BA, due to the high methodological standards set by G-BA and IQWiG, manu-
facturers should de-prioritize this endpoint.
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Objectives: The National Institute of Health and Care Excellence (NICE) makes 
recommendations on which drugs the National Health Service (NHS) should fund, 
with cost-effectiveness being a key criterion. There have been critical media reac-
tions toward NICE appraisals that recommend against funding drugs (particularly 
oncologics), perhaps the most memorable example of which relates to the funding 
of Herceptin in early-stage breast cancer in 2005. This research aimed to evaluate 
how the media currently report NICE decision-making, focussing on the NICE 
appraisal consultation document not recommending Kadcyla on 23rdApril 2014 
with a cost per Quality Added Life Year (QALY) > £180,000, far exceeding typical 
NICE approval thresholds (~£30,000/QALY). MethOds: A selection of national and 
regional newspaper websites, UK broadcasters, press agencies, pharmaceutical 
trade and medical publications were screened for any articles published between 
23rd-25thApril 2014 regarding this NICE draft guidance from which key criteria 
were extracted and compared. Results: 19 articles were extracted (6 national 
newspapers, 6 regional newspapers, 3 broadcasters, and 4 other). 7/19 articles 
primarily focussed on the reaction of a patient/doctor, all of whom were particu-
larly critical of the NICE decision. 3/19 focussed on the high proposed cost of the 
new drug, 2 of which were critical of the pharmaceutical company. 9/19 followed 
the format of briefly summarising the decision and drug, with the majority of 
the article comprising reactions from various sources. However, there was an 
overall numerically higher number of sources in each article criticizing NICE (38, 
mean 2.0 per article) than those defending the NICE decision (21, mean 1.1 per 
article). cOnclusiOns: NICE decisions not to fund oncology drugs still seem to 
be predominantly faced by a hostile media reception that focus more on patient 
reactions than the difficulties of how to allocate finite health care resources to 
best optimise care in the NHS.
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Objectives: The European Medicines Agency (EMA) approved 15 oncologics across 
24 indications based on pivotal single-arm Phase II data (Macaulay, ISPOR Dublin 
2013). Approval was typically granted for indications in which there was no thera-
peutic alternative where a response rate of ≥ 35% was demonstrated. This research 
aims to compare how such data can further support approval between different 
European Health Technology Agencies (HTAs). MethOds: Relevant National 
Institute of Health and Care Excellence (NICE), Scottish Medicines Commission 
(SMC), Commission de la Transparence (CT), Institute for Quality and Efficiency 
in Health Care (IQWiG), Federal Joint Committee (G-BA), and Swedish Dental and 
Pharmaceutical Benefits Agency (TLV) reports were sourced for any oncologic 
approved by the EMA on the basis of pivotal Phase II data (up to March 2014) and 
the decision and key rationale were analysed. Results: CT fully reimbursed 14/14 
(100%) oncologics appraised on the basis of pivotal Phase II data, with 10/14 obtain-
ing ASMRs I-III. In Germany (IQWiG), 6/6 (100%) oncologics appraised on this basis 
were deemed to offer some added benefit, avoiding reference pricing (5/6 were 
orphan drugs which are not subject to a benefit assessment). NICE approved 5/7 
(71%), SMC 6/11 (55%), and TLV 7/7 (100%) of oncologics appraised on Phase II data. 
For NICE/SMC/TLV rejected drugs, the clinical case was not strongly criticised, rather 
cost-utility values were deemed too high and uncertain. Even for approved drugs, 
the lack of comparative data was critiqued as introducing considerable uncertainty 
to submissions. cOnclusiOns: For any oncologic approved by the EMA on the basis 
of Phase II data, favourable ASMR and benefit ratings can be awarded on this basis 
by the CT and IQWiG/G-BA, respectively. NICE, SMC, and TLV recommendations are 
conditional on cost-effectiveness being adequately demonstrated with additional 
price discounts required to offset inherent uncertainties in cost-utility modelling 
from such limited clinical data.
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Objectives: The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable 
cancer patients to gain access to therapies that are not routinely available on the 
NHS. However, this fund has been criticised for providing funding for therapies 
that have not been shown to be cost-effective by the National Institute for Health 
and Care Excellence (NICE). This research aims to define how restrictive criteria 
are for accessing drugs under the CDF and how this compares to access under 
NICE. MethOds: A systematic review of the criteria for accessing drugs accord-
ing to the national CDF list was undertaken and was compared to NICE-published 
statistics for oncology technology appraisals up to 31st March 2014. Results: 
80 oncologic indications have been approved under the CDF, each with specific criteria 
for access and usage. Overall, an average of 5.0 (range 3-11) criteria were specified for 
each drug. Typically, 3 criteria were specified for all drugs: 1) consultant specialist pre-
scriber; 2) specifying the disease; and 3) the line of therapy. However, many agents had 
additional restrictions on top of this, including 20/80 (25%) specifying the performance 
status (14 had 0-1; 6 had 0-2) and 12/80 (15%) to be used within the treating Trust’s 
governance framework as these drugs were not licensed in the specified indication. 
recommendations. Its Dutch counterpart, ZI, issued only 8% of negative decisions 
to TCTs. The mode for a success rate in the Netherlands was special policy that 
enabled reimbursement of TCTs without CEA.
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Objectives: The Cancer Drugs Fund (CDF) was set up in 2011 in England to enable 
patients to access therapies that are not routinely available on the National Health 
Service (NHS). In April 2013, NHS England became responsible for the management 
of the CDF with a single national list of drugs for prioritised funding. As the CDF 
has recently been extended to 2016, it is increasingly important to understand 
the key criteria for inclusion on the CDF-approved list, which this research aims 
to define. MethOds: CDF appraisal reports were sourced from the NHS England 
website (April 2013 – March 2014) and the date, decision, and key rationale were 
extracted. Results: 56 CDF decision summaries were available, 14 (25%) received 
full approval, 10 (18%) received conditional/restricted approval, 28 (50%) were 
rejected, and 4 (7%) were referred to commissioning. The key clinical attributes 
of each oncologic were given a numerical scoring that sum to a possible maxi-
mum +21 and minimum -4. The maximum score of any drug appraised was +8 
and the minimum was -1. Excluding appraisals referred to commissioning, 16/18 
appraisals scoring < 2 were rejected (89%) compared to only 5/25 (20%) scoring > = 2 
(4/5 primarily due to trial comparator choice). 9 were not scored due to a lack of 
appropriate evidence. 11 submissions were only based on Phase II data (for such 
submissions, efficacy scores were halved), 5 of which were approved. cOnclusiOns: 
A score of > = 2 seems to be the key clinical threshold above which most 
drugs are CDF-approved, below which most are rejected. Given that 43/47 scoring 
drugs scored -1 for toxicity, this means that 3 points are typically required, which 
can come through a 4-5 month Progression Free Survival or Overall Survival gain (or 
a 2-3 month gain in both), but this must be versus the clinically relevant comparator.
PCN252
testiNg the utility of the Nhs’s systeMiC aNti-CaNCer theraPy data 
set for Multi-iNdiCatioN PriCiNg
McNamara L., McNamara S.
Roche Products Ltd., Welwyn Garden City, UK
Objectives: The price of a medicine should reflect the value it offers to patients, 
the health care system and society more broadly. However, with current pricing 
manufacturers can only set the price of a product based upon the cost per unit of 
that product. This may result in a price being set which society considers as being as 
‘too high’ in certain indications. This apparent mismatch in value and cost can lead 
to patients being denied access to medicine in certain indications. MethOds: The 
implementation of a pricing model where there is differentiated value of a medi-
cine across indications, line of therapy or if used as a mono/combination therapy 
requires the use of real world drug utilisation data. The Personalised Reimbursement 
Models project is at the forefront of the development and implementation of innova-
tive pricing approaches in the UK. This project includes identifying and developing 
the infrastructure required in order to introduce Multi-Indication Pricing (MIP) into 
the NHS in the UK. We have worked alongside NHS Trusts and national bodies in 
a joint working project to validate and test the utility of the Systemic Anti-Cancer 
Therapy (SACT) dataset. Results: This joint working project demonstrates that 
SACT has the potential to allow implementation of MIP in England. cOnclusiOns: 
Following completion of this work we hope SACT will be used to introduce MIP in 
England - this will eliminate the administrative pharmacy burden of data collection 
for commercial schemes for cancer medicines, enabling medicines to be priced 
for the value they provide in each of their uses and ensure that patients are not 
disadvantaged due to having a condition potentially treatable by a product with 
multiple indications.
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Objectives: Since AMNOG reform has taken effect 3.5 years ago, 78 dossiers have 
been evaluated by the G-BA. Especially with oncology agents, 28 products have 
started the process and G-BA has finalized decisions for 25 dossiers. In 20 cases addi-
tional benefit was granted. Therefore, the success rate of oncology products is 80% 
and much higher than the success rate of non-oncology products (29%). MethOds: 
An analysis of all oncology assessments will reveal key drivers responsible for the 
positive assessments by IQWiG and G-BA. Beside the study design (H2H vs. indirect 
comparison), and comparator choice the analysis will focus on submitted end-
points. It will be evaluated which endpoints contribute most in oncology indications 
to additional benefit. Results: Additional benefit is assessed based on patient 
relevant endpoints (mortality, morbidity, quality of life & safety). More than 55% 
of submitted endpoints fall in the safety category, followed by morbidity (approx. 
30%), mortality (approx. 10%) and quality of life (approx. 5%). The most important 
endpoint is mortality (OS), where the G-BA granted additional benefit in 18 out 
of 20 dossiers primarily based on OS data. In terms of morbidity, PFS, ORR and 
“Time to Pain Progression” are the top three most submitted morbidity endpoints; 
however, only “Time to Pain Progression” led to additional benefit in 2 out of 3 
cases. Only in one case quality of life contributed to the overall additional benefit 
decision. cOnclusiOns: OS will continue to be the most additional benefit con-
tributing endpoint in oncology. In the absence of OS, PFS will not help in the overall 
additional benefit decision by G-BA, unless the MNF can justify PSF to be patient 
relevant according to IQWiG methodology. Although QoL is an accepted endpoint 
